ArticleExperimental and therapeutic medicine2025
Prostate artery embolization as an effective treatment for clinically significant prostate cancer‑related hemorrhage: A case report.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Prostatic artery embolization for palliative control of hematuria in locally advanced or metastatic prostate cancer: a systematic review.Abdominal radiology (New York) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 79-year old Caucasian male with metastatic hormone refractory prostate cancer and bilateral nephrostomy was admitted to the emergency department due to 4-day bloody urethral discharge, weakness and dizziness. The patient was treated with the luteinizing hormone-releasing hormone-antagonist and abiraterone acetate plus prednisone, dabigatran 150 mg bid (for atrial fibrillation and coronary heart disease) and 5-aminosalicylic acid for the management of mild ulcerative colitis. Imaging revealed bladder overdistention and blood analysis low levels of hematocrit (HCT) and hemoglobin (HGB) (HCT, 22%; HGB, 7.1 gr/dl). A 22F, 3-way urethral catheter was placed, and blood clots were removed with a syringe. Continuous normal saline irrigation was initiated, and the dabigatran was withdrawn; however, no evidence of control of blood loss was shown. Computed tomography and urography revealed a large prostate lesion invading the bladder neck, a pelvic lymph-node block and lack of blood extravasation. Diagnostic urethrocystoscopy revealed diffuse hematuria from the prostate lesion and bladder neck. Bipolar coagulation was performed in the absence of any significant improvement. Upon withdrawal of intravesical irrigation, the oral consumption of a large water volume (a useful measure to control hematuria and avoid clot formation) could not be applied to the patient due to urine storage and normal voiding being not feasible. Subsequently, the patient was informed on the option of superselective arterial embolization (SAE). Following signing of the relevant consent form, the patient underwent bilateral SAE of prostatic and inferior cystic arteries, while he was in heparin delivery. Dabigatran was re-administered on the 5th postprocedural day and the catheter was removed following 5 days. Following a 4-month follow-up, the patient's condition was stable with no traceable hematuria. In conclusion, the minimal invasiveness of SAE is an attractive option, notably in patients with cardiovascular comorbidities. It appears to be a safe alternative with an acceptable rate of minor complications. The encouraging results and the survival outcomes warrant further evaluation with comparative prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.